Amylin at the interface between metabolic and neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pancreatic peptide amylin is best known for its role as a satiation hormone in the control of food intake and as the major component of islet amyloid deposits in the pancreatic islets of patients with type 2 diabetes mellitus (T2DM). Epidemiological studies have established a clear association between metabolic and neurodegenerative disorders in general, and between T2DM and Alzheimer's disease (AD) in particular. Here, we discuss that amylin may be an important player acting at the interface between these metabolic and neurodegenerative disorders. Abnormal amylin production is a hallmark peripheral pathology both in the early (pre-diabetic) and late phases of T2DM, where hyperamylinemic (early phase) and hypoamylinemic (late phase) conditions coincide with hyper- and hypo-insulinemia, respectively. Moreover, there are notable biochemical similarities between amylin and β-amyloids (Aβ), which are both prone to amyloid plaque formation and to cytotoxic effects. Amylin's propensity to form amyloid plaques is not restricted to pancreatic islet cells, but readily extends to the CNS, where it has been found to co-localize with Aβ plaques in at least a subset of AD patients. Hence, amylin may constitute a "second amyloid" in neurodegenerative disorders such as AD. We further argue that hyperamylinemic conditions may be more relevant for the early processes of amyloid formation in the CNS, whereas hypoamylinemic conditions may be more strongly associated with late stages of central amyloid pathologies. Advancing our understanding of these temporal relationships may help to establish amylin-based interventions in the treatment of AD and other neurodegenerative disorders with metabolic comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 7×
“According to one hypothesis, prolonged hyperglycemia may lead to a higher concentration of pro-amylin within the β-cells (Hou et al., 1999), which in turn may create a core for amylin aggregation and ultimately cause β-cell loss and deposition of extracellular amyloid (Paulsson and Westermark,…”
BackgroundInfluentialWang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864 · cited 2×
“It has been further shown that the effects of RAMP1 overexpression on energy expenditure are mediated by an increased sympathetic tone in efferents innervating BAT (Zhang et al., 2011; Fernandes-Santos et al., 2013).”
BackgroundPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“The global prevalence of dementia is currently estimated to be as high as 30–40 million, and is predicted to quadruple by the year 2050 (Reitz et al., 2011; Hurd et al., 2013; Reitz and Mayeux, 2014).”
BackgroundMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“Increased inflammatory processes in general, and overproduction of IL-1β in particular, may represent another important mechanism by which amylin aggregation can cause β-cell death (Masters et al., 2010; Donath and Shoelson, 2011; Westwell-Roper et al., 2011; Donath et al., 2013).”
BackgroundAlzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“…uptake and subsequent emergence of central hypometabolism, mitochondrial dysfunction and oxidative stress, cerebro-vascular disruption, as well as imbalances in neuroinflammatory reactions (reviewed in de la Monte and Wands, 2008; de la Monte, 2012; Bassil et al., 2014; Sebastião et al., 2014).”
BackgroundIslet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044 · cited 3×
“Hyperamylinemia is frequently observed in individuals with obesity or pre-diabetic insulin resistance (Johnson et al., 1989; Enoki et al., 1992) and often coincides with hyperinsulinemia (Westermark et al., 2011).”
BackgroundROS, mitochondria and the regulation of autophagy
Scherz-Shouval, R., & Elazar, Z. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.009 · Cited by 954 · cited 2×
“Increased ROS levels may ultimately lead to significant damage to cell structures and cause cell loss (Parks et al., 2001; Scherz-Shouval and Elazar, 2007; Gurlo et al., 2010).”
BackgroundOxidative stress in Alzheimer’s disease
Chen, Z., & Zhong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1423-y · Cited by 797 · cited 1×
“These include increased oxidative stress, neuroinflammation, and impairments in brain glucose uptake and metabolism (Eikelenboom et al., 2010; Bassil et al., 2014; Chen and Zhong, 2014; Morales et al., 2014).”
BackgroundMorales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486
Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells
Kahn, S. E., D'Alessio, D. A., Schwartz, M. W., Fujimoto, W. Y., Ensinck, J. W., Taborsky, G. J., & Porte, D. (1990) · Diabetes · doi:10.2337/diab.39.5.634 · Cited by 454 · cited 1×
“Amylin is a pancreatic β-cell hormone co-released with insulin in response to food intake (Kahn et al., 1990).”
BackgroundButterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
Common cellular and molecular mechanisms in obesity and drug addiction
Kenny, P. J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3105 · Cited by 382 · cited 2×
“It has been further shown that the effects of RAMP1 overexpression on energy expenditure are mediated by an increased sympathetic tone in efferents innervating BAT (Zhang et al., 2011; Fernandes-Santos et al., 2013).”
BackgroundThe Addictive Dimensionality of Obesity
Volkow, N. D., Wang, G.-J., Tomasi, D., & Baler, R. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.020 · Cited by 380 · cited 2×
“The mesolimbic dopamine system has long been recognized to play a crucial role in reward processing including eating associated rewards (Berridge and Robinson, 1998; Volkow et al., 2013).”
BackgroundCommon pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338 · cited 2×
“Abnormalities in the processing of amylin and its deposition as amyloid in the islets may contribute to the progressive loss of pancreatic β-cells, which is a pathological hallmark of T2DM.”
BackgroundAmyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · cited 6×
“The maintenance of physiological conditions is further dependent on the equilibrium between the production of (soluble) Aβ peptides and their clearance from the brain (Ueno et al., 2014; Baranello et al., 2015).”
BackgroundInfluentialβ-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition
Jurgens, C. A., Toukatly, M. N., Fligner, C. L., Udayasankar, J., Subramanian, S. L., Zraika, S., Aston-Mourney, K., Carr, D. B., Westermark, P., Westermark, G. T., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.036 · Cited by 329 · cited 4×
“Islet amyloid formation plays a key role in β-cell apoptosis and dysfunction as seen in T2DM (Westermark et al., 2000, 2011; Paulsson andWestermark, 2005; Höppener and Lips, 2006; Jurgens et al., 2011).”
BackgroundInfluentialde la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265 · cited 3×
“…uptake and subsequent emergence of central hypometabolism, mitochondrial dysfunction and oxidative stress, cerebro-vascular disruption, as well as imbalances in neuroinflammatory reactions (reviewed in de la Monte and Wands, 2008; de la Monte, 2012; Bassil et al., 2014; Sebastião et al., 2014).”
BackgroundFerrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174 · cited 1×
“AD patients typically show progressive cognitive decline along with the concomitant appearance of several neuropathological hallmarks, including amyloid plaque deposition, neurofibrillary tangle formation, vascular malfunction, and synaptic loss (Ferrer, 2012).”
BackgroundIslet Amyloid Polypeptide (IAPP) Transgenic Rodents as Models for Type 2 Diabetes
Matveyenko, A. V., & Butler, P. C. (2006) · ILAR Journal · doi:10.1093/ilar.47.3.225 · Cited by 150 · cited 6×
“The reason for this species differences is that only the former contain an amyloidogenic region within their amino acid sequence that is essential for amyloid formation and toxicity (Betsholtz et al., 1989; Höppener et al., 1994; Moriarty and Raleigh, 1999; Matveyenko and Butler, 2006).”
BackgroundInfluentialEnoki, S., Mitsukawa, T., Takemura, J., Nakazato, M., Aburaya, J., Toshimori, H., & Matsukara, S. (1992) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(92)90074-2 · Cited by 118 · cited 3×
“Hyperamylinemia is frequently observed in individuals with obesity or pre-diabetic insulin resistance (Johnson et al., 1989; Enoki et al., 1992) and often coincides with hyperinsulinemia (Westermark et al., 2011).”
BackgroundZhu, H., Wang, X., Wallack, M., Li, H., Carreras, I., Dedeoglu, A., Hur, J.-Y., Zheng, H., Li, H., Fine, R., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.17 · Cited by 108
Cited by
de Mello, V. D., Paananen, J., Lindström, J., Lankinen, M. A., Shi, L., Kuusisto, J., Pihlajamäki, J., Auriola, S., Lehtonen, M., Rolandsson, O., et al. (2017) · Scientific Reports · doi:10.1038/srep46337 · Cited by 379
Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
“Like insulin, amylin levels are higher than normal in patients with obesity or insulin resistance, while the coexistence of hyperinsulinemia and hyperamylinemia is common [131,132].”
BackgroundLutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59
Self-citationPeripheral insulin and amylin levels in Parkinson's disease
Sánchez-Gómez, A., Alcarraz-Vizán, G., Fernández, M., Fernández-Santiago, R., Ezquerra, M., Cámara, A., Serrano, M., Novials, A., Muñoz, E., Valldeoriola, F., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.08.018 · Cited by 44
Metadata
- Authors
- Lutz, T. A., & Meyer, U.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-06-16
- Volume
- 9
- Pages
- 216-216
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W1580414793
- Cited by
- 100
- References
- 27
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.